Published in Eur J Pediatr on August 13, 2002
Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy. Nat Rev Endocrinol (2010) 1.32
Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis (2008) 1.28
Is Crohn's disease due to defective immunity? Gut (2007) 1.21
Retracted Biologic targeting in the treatment of inflammatory bowel diseases. Biologics (2009) 1.20
New insights into the dichotomous role of innate cytokines in gut homeostasis and inflammation. Cytokine (2012) 1.17
Glucose-6-phosphatase deficiency. Orphanet J Rare Dis (2011) 1.12
Innate immunity in inflammatory bowel disease: a disease hypothesis. J Pathol (2008) 1.08
Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease. Hum Mutat (2008) 1.03
Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment Pharmacol Ther (2006) 1.02
Biologics in inflammatory bowel disease: how much progress have we made? Gut (2004) 0.99
Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol (2010) 0.98
Adult siblings with homozygous G6PC3 mutations expand our understanding of the severe congenital neutropenia type 4 (SCN4) phenotype. BMC Med Genet (2012) 0.94
Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J Inherit Metab Dis (2008) 0.89
Myasthenia gravis in a patient affected by glycogen storage disease type Ib: a further manifestation of an increased risk for autoimmune disorders? J Inherit Metab Dis (2008) 0.86
The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life (2010) 0.83
Inflammatory bowel disease and T cell lymphopenia in G6PC3 deficiency. J Clin Immunol (2012) 0.80
Smoking and inflammatory bowel diseases: what in smoking alters the course? Int J Colorectal Dis (2010) 0.80
Treatment of Crohn's disease with colony-stimulating factors: An overview. Ther Clin Risk Manag (2008) 0.76
The SLC37 family of phosphate-linked sugar phosphate antiporters. Mol Aspects Med (2013) 0.76
Making sense of the cause of Crohn's - a new look at an old disease. F1000Res (2016) 0.75
Cutting Edge: Increased Autoimmunity Risk in Glycogen Storage Disease Type 1b Is Associated with a Reduced Engagement of Glycolysis in T Cells and an Impaired Regulatory T Cell Function. J Immunol (2017) 0.75
The role of innate immunity in Crohn's disease. Gastroenterol Hepatol (N Y) (2007) 0.75
Human Metabolic Enzymes Deficiency: A Genetic Mutation Based Approach. Scientifica (Cairo) (2016) 0.75
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
A prospective study of long-term intake of dietary fiber and risk of Crohn's disease and ulcerative colitis. Gastroenterology (2013) 4.06
Higher predicted vitamin D status is associated with reduced risk of Crohn's disease. Gastroenterology (2011) 3.84
Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.88
Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet (2002) 2.74
LRRK2 is involved in the IFN-gamma response and host response to pathogens. J Immunol (2010) 1.85
A review on therapeutic potential of Nigella sativa: A miracle herb. Asian Pac J Trop Biomed (2013) 1.84
Non-invasive mapping of the gastrointestinal microbiota identifies children with inflammatory bowel disease. PLoS One (2012) 1.66
Dysregulation of Reg gene expression occurs early in gastrointestinal tumorigenesis and regulates anti-apoptotic genes. Cancer Biol Ther (2006) 1.63
Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J Med Microbiol (2009) 1.58
Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J Pediatr Gastroenterol Nutr (2009) 1.22
Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ (2013) 1.18
Probiotics for recurrent Clostridium difficile disease. J Med Microbiol (2005) 1.06
Impact of coexistent celiac disease on phenotype and natural history of inflammatory bowel diseases. Am J Gastroenterol (2013) 1.05
Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort. Inflamm Bowel Dis (2015) 0.99
Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease. Gut (2011) 0.97
Chemical and cytokine features of innate immunity characterize serum and tissue profiles in inflammatory bowel disease. Proc Natl Acad Sci U S A (2013) 0.97
Analysis of treatment effects on the microbial ecology of the human intestine. FEMS Microbiol Ecol (2006) 0.96
Inflammatory bowel disease and environmental influences. Gastroenterol Clin North Am (2002) 0.95
Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis (2013) 0.93
Marijuana use patterns among patients with inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.92
Efficacy and safety of natalizumab in Crohn's disease patients treated at 6 Boston academic hospitals. Inflamm Bowel Dis (2013) 0.92
Distinct microbiome in pouchitis compared to healthy pouches in ulcerative colitis and familial adenomatous polyposis. Inflamm Bowel Dis (2010) 0.92
Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. Inflamm Bowel Dis (2011) 0.89
Certolizumab pegol compared to natalizumab in patients with moderate to severe Crohn's disease: results of a decision analysis. Dig Dis Sci (2011) 0.86
Aroylpropionic acid based 2,5-disubstituted-1,3,4-oxadiazoles: synthesis and their anti-inflammatory and analgesic activities. Eur J Med Chem (2008) 0.86
Growth factors as treatment options for intestinal inflammation. Ann N Y Acad Sci (2006) 0.86
Barriers to enrollment in inflammatory bowel disease randomized controlled trials: an investigation of patient perspectives. Inflamm Bowel Dis (2012) 0.85
Validation of interactive voice response system administration of the Short Inflammatory Bowel Disease Questionnaire. Inflamm Bowel Dis (2009) 0.85
Risk Factors for Rehospitalization Within 90 Days in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2015) 0.82
Immediate versus tailored prophylaxis to prevent symptomatic recurrences after surgery for ileocecal Crohn's disease? Surgery (2011) 0.81
Strategies for the prevention of postoperative recurrence in Crohn's disease: results of a decision analysis. Am J Gastroenterol (2011) 0.81
Synthesis and pharmacological evaluation of 2(3H)-furanones and 2(3H)-pyrrolones, combining analgesic and anti-inflammatory properties with reduced gastrointestinal toxicity and lipid peroxidation. Eur J Med Chem (2008) 0.81
Selective use of selective nonsteroidal anti-inflammatory drugs in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 0.80
Synthesis of 6-aminomethyl derivatives of benzopyran-4-one with dual biological properties: anti-inflammatory-analgesic and antimicrobial. Eur J Med Chem (2009) 0.80
Microwave assisted one pot synthesis of some pyrazole derivatives as a safer anti-inflammatory and analgesic agents. Acta Pol Pharm (2013) 0.79
Antihepatotoxic activity of aqueous extracts of callus culture of Tephrosia purpurea (L) pers. Acta Pol Pharm (2012) 0.78
Modifiable Risk Factors for Hospital Readmission Among Patients with Inflammatory Bowel Disease in a Nationwide Database. Inflamm Bowel Dis (2017) 0.77
Anticancer activity of new compounds using benzimidazole as a scaffold. Anticancer Agents Med Chem (2014) 0.77
Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents. Eur J Med Chem (2012) 0.77
Search for new pharmacophore as antimalarial agent: synthesis and antimalarial activity of some 2(3H)-furanones bearing quinoline moiety. Acta Pol Pharm (2011) 0.76
Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis (2015) 0.76
Synthesis and in-vitro antimycobacterial activity of amino-5-[(substituted) phenyl]-3-(4-hydroxy-3-methylphenyl)-4,5-dihydro-1H-1-pyrazolylmethanethione. Acta Pol Pharm (2008) 0.75
Synthesis of some new 2-(substituted-phenyl)-5-(N,N-diphenylaminomethyl)-1,3,4-oxadiazoles: a safer anti-inflammatory and analgesic agents. Acta Pol Pharm (2011) 0.75
New 4,6-diacetyl resorcinol Mannich bases: synthesis and biological evaluation. Acta Pol Pharm (2010) 0.75
Hospitalizations for Acute Myocardial Infarction Are Decreased Among Patients with Inflammatory Bowel Disease Using a Nationwide Inpatient Database. Inflamm Bowel Dis (2016) 0.75
Triazole incorporated pyridazinones as a new class of antihypertensive agents: design, synthesis and in vivo screening. Bioorg Med Chem Lett (2010) 0.75
Design, synthesis and antihypertensive screening of novel pyridazine substituted s-triazin-2-imine/one/thione derivatives. J Enzyme Inhib Med Chem (2012) 0.75
Crohn's Cartography: Mapping Disease Patterns and Trajectories Using the Lémann Index-Are We Finding Our Way? J Clin Gastroenterol (2016) 0.75
Anti-inflammatory and antimicrobial activity of 4,5-dihydropyrimidine-5-carbonitrile derivatives: their synthesis and spectral elucidation. Acta Pol Pharm (2013) 0.75
3-arylidene-5-(4-isobutylphenyl)-2(3H)-furanones: a new series of anti-inflammatory and analgesic compounds having antimicrobial activity. J Enzyme Inhib Med Chem (2010) 0.75
Analytical methods for the detection of undeclared synthetic drugs in traditional herbal medicines as adulterants. Drug Test Anal (2013) 0.75
Impaired innate immune function associated with fecal supernatant from Crohn's disease patients: insights into potential pathogenic role of the microbiome. Inflamm Bowel Dis (2014) 0.75